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DOI 10.1186/s12885-015-1195-zRESEARCH ARTICLE Open AccessCirculating tumor cells in hepatocellular carcinoma:
a pilot study of detection, enumeration, and
next-generation sequencing in cases and controls
Robin K Kelley1*, Mark Jesus M Magbanua2, Timothy M Butler3, Eric A Collisson2, Jimmy Hwang2,
Nikoletta Sidiropoulos4, Kimberley Evason5, Ryan M McWhirter2, Bilal Hameed6, Elizabeth M Wayne7, Francis Y Yao8,
Alan P Venook1 and John W Park2Abstract
Background: Circulating biomarkers are urgently needed in hepatocellular carcinoma (HCC). The aims of this study
were to determine the feasibility of detecting and isolating circulating tumor cells (CTCs) in HCC patients using
enrichment for epithelial cell adhesion molecule (EpCAM) expression, to examine their prognostic value, and to
explore CTC-based DNA sequencing in metastatic HCC patients compared to a control cohort with non-malignant
liver diseases (NMLD).
Methods: Whole blood was obtained from patients with metastatic HCC or NMLD. CTCs were enumerated by
CellSearch then purified by immunomagnetic EpCAM enrichment and fluorescence-activated cell sorting. Targeted
ion semiconductor sequencing was performed on whole genome-amplified DNA from CTCs, tumor specimens, and
peripheral blood mononuclear cells (PBMC) when available.
Results: Twenty HCC and 10 NMLD patients enrolled. CTCs≥ 2/7.5 mL were detected in 7/20 (35%, 95%
confidence interval: 12%, 60%) HCC and 0/9 eligible NMLD (p = 0.04). CTCs≥ 1/7.5 mL was associated with
alpha-fetoprotein≥ 400 ng/mL (p = 0.008) and vascular invasion (p = 0.009). Sequencing of CTC DNA identified
characteristic HCC mutations. The proportion with≥ 100x coverage depth was lower in CTCs (43%) than tumor or
PBMC (87%) (p < 0.025). Low frequency variants were higher in CTCs (p < 0.001).
Conclusions: CTCs are detectable by EpCAM enrichment in metastatic HCC, without confounding false positive
background from NMLD. CTC detection was associated with poor prognostic factors. Sequencing of CTC DNA
identified known HCC mutations but more low-frequency variants and lower coverage depth than FFPE or PBMC.
Keywords: Hepatocellular carcinoma (HCC), Circulating tumor cells (CTC), EpCAM, SequencingBackground
Hepatocellular carcinoma (HCC) is a grim, heteroge-
neous disease with limited treatment options despite its
enormous global impact as the third leading cause of
cancer death worldwide [1]. Conventional liver imaging
modalities for diagnosis and staging are imprecise and
can result in underestimation of the true extent of dis-
ease, with microvascular invasion and multifocal tumors* Correspondence: Katie.kelley@ucsf.edu
1Helen Diller Family Comprehensive Cancer Center and The Liver Center,
University of California San Francisco (UCSF), 550 16th St., Box 3211, San
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unless otherwise stated.often identified incidentally at resection or transplant
and associated with significantly poorer prognosis [2,3].
Translational research efforts to better understand the
complex tumor biology of HCC, define biomarkers, and
identify novel therapeutic targets are further limited by a
scarcity of annotated, untreated tumor specimens, owing
to the acceptance of radiographic diagnosis without tis-
sue confirmation, the prevalence of liver-directed ther-
apy before transplantation, and the risks associated with
tumor biopsy in this population [4,5]. Non-invasive bio-
markers for diagnosis and molecular characterization are
urgently needed to overcome these pervasive challenges
in HCC.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are a biomarker of poor prognosis in multiple epithelial
tumor types [6,7]. The CellSearch System (Veridex LLC,
Raritan, New Jersey, U.S.A) is an FDA-cleared device for
CTC detection using enrichment for cells in the blood
expressing the epithelial cell adhesion marker (EpCAM)
[6]. The absolute numbers of CTCs detected and
changes on therapy have been associated with survival
and treatment response in breast, colon, and prostate
cancers [8-13]. Multiple small studies have examined
CTCs in patients with HCC using EpCAM- and non-
EpCAM-based enrichment methods, with detection
rates ranging from approximately 30% to over 80% de-
pending on methodology and population [14-17]. As in
other epithelial tumor types, the detection of CTCs by
CellSearch correlates with poor prognosis in HCC co-
horts, including increased recurrence risk after resection
and shorter overall survival [14,15].
In order to study CTCs as a biomarker in HCC, how-
ever, it is essential to establish that circulating epithelial
cells in HCC populations are true tumor cells, rather
than benign epithelial cells released into circulation as a
consequence of the underlying inflammation or aberrant
vasculature associated with liver disease. Though the de-
tection of CTCs by CellSearch is extremely rare in
healthy volunteers or patients with benign conditions
[6,10], there is limited data describing the incidence of
circulating EpCAM-positive epithelial cells in the con-
text of cirrhosis, viral hepatitis, or other causes of liver
injury, conditions present in the majority of patients
with HCC [14].
Beyond detection and enumeration, isolation of CTCs
in cancer patients holds great promise as a “liquid bi-
opsy”, a non-invasive means of accessing real-time
tumor tissue in the metastatic state for molecular profil-
ing. Array comparative genomic hybridization has dem-
onstrated concordance of characteristic copy number
aberrations between CTC-derived DNA and archival pri-
mary tumor samples in breast, colon, prostate, and lung
cancer [12,18-20]. Next-generation sequencing technolo-
gies now have the ability to sequence very small
amounts of input DNA with high accuracy [21,22].
Illumina MiSeq technology can detect characteristic
driver mutations in single CTCs derived from patients
with metastatic colorectal cancer, concordant with the
mutational profile of paired primary tumor specimens
[18]. To date, the feasibility of efficient CTC isolation
and molecular profiling, e.g. next-generation DNA se-
quencing, has not been reported in HCC.
We conducted this study to determine the proportion
of metastatic HCC patients with detectable circulating
EpCAM-positive epithelial cells using the CellSearch
System, compared to a relevant control cohort of pa-
tients with liver disease, hypothesizing that circulatingEpCAM-positive cells are actual tumor cells rather than
benign epithelial cells. To characterize their prognostic
significance, CTC levels were examined for association
with clinical covariates including alpha-fetoprotein (AFP)
levels, the presence of vascular invasion, and overall sur-
vival. To explore the potential for CTCs to serve as a
source of tumor DNA for genomic profiling in HCC,
next-generation sequencing using a targeted cancer gene
panel was performed using whole genome-amplified DNA
derived from pooled purified CTCs, along with DNA from
paired archival, paraffin-embedded tumor tissue and per-
ipheral blood mononuclear cells when available.
Methods
Study design
This pilot study was a non-therapeutic, minimally-
invasive biomarker study. The trial was approved by the
UCSF Committee on Human Research. All patients pro-
vided written informed consent for specimen collection
and genetic testing of tumor and germline DNA. The
study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice.
The primary endpoint was incidence of CTCs detected
in metastatic HCC patients compared to a control co-
hort with NMLD. Secondary endpoints were enumer-
ation of CTCs in each cohort, association with clinical
and pathologic characteristics including alpha fetopro-
tein (AFP) level, tumor vascular invasion, and etiology of
liver disease in the HCC cohort, and association with
overall survival in the HCC cohort. An exploratory end-
point was to describe performance of and somatic muta-
tions identified by next-generation sequencing of CTC
whole-genome-amplified DNA along with paired tumor
and germline DNA when available.Patient selection
HCC patients were recruited at the UCSF Helen Diller
Family Comprehensive Cancer Center. Principal inclu-
sion criteria were: radiographic [4] or histologic diagno-
sis of American Joint Committee on Cancer (AJCC)
stage IV HCC; ≥ 6 weeks post biopsy, surgery, liver-
directed interventions, or other invasive procedures; no
prior systemic therapy or ≥ 4 weeks since last dose of so-
rafenib or other systemic therapy for advanced HCC.
Non-malignant liver disease (NMLD) control cohort pa-
tients were recruited at the UCSF Gastroenterology and
Liver Disease Clinic. Principal inclusion criteria were:
diagnosis of active hepatitis of any etiology plus clinical
or pathologic diagnosis of cirrhosis or hepatic fibrosis
(any stage); no evidence liver tumor on ultrasound or
cross-sectional imaging within 6 months; AFP ≤ 20 ng/mL
within 6 months; ≥ 6 weeks post biopsy, surgery, or other
invasive procedures; no prior history of HCC.
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Approximately 30 mL of whole blood was obtained from
study subjects at a single time-point. For HCC patients
with available archival tumor tissue from prior biopsy or
resection, approximately five 10-micron sections of
formalin-fixed, paraffin-embedded (FFPE) tumor along
with a matching H&E slide were collected from the path-
ology files of the University of California, San Francisco.
Banked frozen aliquots of peripheral blood mononuclear
cell (PBMC) were obtained when available from HCC
cohort patients.
Circulating tumor cell enumeration
CTCs were isolated from 7.5 mL whole blood and enu-
merated using the CellSearch System (Veridex LLC,
Raritan, NJ) [6-8]. Briefly, specific antibodies to EpCAM
were used to enrich for epithelial cells. A mixture of
fluorescently-labeled monoclonal antibodies to cytokera-
tin and the nuclear dye DAPI were used to select for
nucleated, keratin-positive cells. CTCs were defined as
nucleated, EpCAM-positive cells that stain positive for
cytokeratin and negative for leukocyte common antigen,
CD45 [6]. Labeled cells were enumerated using semi-
automated fluorescence-based microscopy. Analysis was
performed by a trained technician blinded to diagnosis
(HCC versus NMLD).
Immunoenrichment and fluorescence-activated cell
sorting (IE/FACS)
A novel EpCAM-based immunoenrichment (IE)/fluores-
cence-activated cell sorting (FACS) procedure has been
developed to isolate purified CTCs without contamin-
ation from normal blood cells and has demonstrated
correlation with CellSearch System CTC enumeration
[12,19,23]. For patients found to have > 10 CTCs in
7.5 mL of whole blood by CellSearch System, IE/FACS
was then performed to isolate purified CTCs as has been
previously described [12,24]. Briefly, approximately 15–
20 mL of whole blood was incubated with immunomag-
netic particles coated with two different monoclonal
antibodies to EpCAM, one conjugated to magnetic parti-
cles and the other to a fluorophore. FACS was used to
isolate nucleated, EpCAM-positive, CD45-negative cells.
Whole genome amplification (WGA)
A ligation-adaptor method of WGA was performed on
whole cell lysates from pooled CTCs isolated by IE/
FACS using a GenomePlex whole genome amplification
kit (WGA4, Sigma-Aldrich) according to the manufac-
turer’s instructions [12,25]. DNA was randomly frag-
mented and converted to polymerase chain reaction
(PCR)-amplifiable library molecules flanked by universal
priming sites. PCR amplification of library molecules
was performed using universal oligonucleotide primers.DNA extraction from tumor tissue and peripheral blood
mononuclear cells (PBMC)
Tumor-containing FFPE sections were identified and
marked by a hepatopathologist (KE). DNA was ex-
tracted from FFPE sections as well as from banked
PBMC using QIAmp kits (Qiagen) according to the
manufacturer’s instructions. DNA concentration was
quantified using PicoGreen.
Ion semiconductor NGS
Sequencing of DNA extracted from CTCs, FFPE, and
PBMC was performed by TMB in the Spellman Laboratory
at Oregon Health Sciences University. From each sample,
10 ng DNA was PCR-amplified using AmpliSeq Cancer
Panel Primer Pools and Library Kit 2.0 to generate 190
multiplexed amplicons (representing 46 cancer-related
genes) [21]. Up to 11 barcoded samples were multiplexed
on Ion 318 chips. Sequencing was performed on a Personal
Genome Machine (PGM) sequencer (Ion Torrent) using
the Ion PGM 200 sequencing kit. Torrent Suite software
version 4.0.1 was employed to analyze read counts and
quality. Variant Caller software version 4.0.1 identified vari-
ants. Coverage Analysis software version 4.0.1 determined
target coverage. To minimize false positives, variants were
required to have sequencing depth of at least 20x, an allele
frequency of 5 percent, and not be present in any of the 3
PBMC samples sequenced. Variant calls were filtered
against the Single Nucleotide Polymorphism Database
(dbSNP) version 132, using the software ANNOVAR.
Protein-altering variants were predicted by Mutation Asses-
sor version 2 (http://mutationassessor.org).
Statistical analysis
Based upon the a priori hypothesis that approximately
50% of the HCC cohort and none of the NMLD cohort
would have detectable CTCs by CellSearch, the planned
sample size for this pilot study was 20 patients with
metastatic HCC and 10 patients with NMLD, to permit
estimation of proportion of detectable CTCs with 95%
confidence intervals (CI) as (0.30, 0.70) in the HCC
cohort and (0.01, 0.26) in the NMLD cohort. The inci-
dence and number of detectable CTCs were analyzed
using frequency and proportions with 95% CI and com-
pared between HCC and NMLD cohorts using the
Wilcoxon-Kruskal-Wallis rank test. Cut-points of ≥ 1, ≥ 2,
≥ 3, and ≥ 5 CTCs/7.5 mL were examined based upon pub-
lished literature in HCC and other tumor types
[8,10,14,15]. Wilcoxon-Kruskal-Wallis rank testing was also
used to determine association between the presence of de-
tectable CTCs by CellSearch System, AFP elevation using
≥ 400 ng/mL as an established prognostic cut-point [26,27],
and the presence of vascular invasion (all binary variables).
In the HCC cohort, overall survival was measured in
months from date of CTC blood draw to the date of death
Table 1 Patient characteristics
HCC cohort
(n = 20)
NMLD control
Cohort (n = 10)
Median age (range) (years) 61.5 (50–82) 26-91 (53.5)
Male/female (n) 20/0 9/1
Etiology of liver disease (%)
HBV 25 20
HCV 45 60
Co-infection HBV + HCVa 10 0
ETOH 5 10
NAFLD 10 0
PSC 0 10
Unknown 5 0
Race/ethnicity (%)
African-American 5 10
Asian 35 10
Caucasian 55 70
Hispanic/Latino 5 30
Non-Hispanic/Latino 50 40
Native American 5 0
Other/unknown 0 10
Child Pugh score (%)
A/B/C/unknown 70/25/5/0 30/30/30/10
Median AFP (range) (ng/mL) 492 (3.8-587,134) 5.5 (1.7-17.2)
BCLC score C (%)b 100 N/A
Vascular invasion (%) 65 N/A
Extrahepatic spread (%)b 100 N/A
Median overall survival (months) 9.4 months Not measured
Key: HBV = hepatitis B virus. HCV = hepatitis C virus. ETOH= alcohol. NAFLD=
non-alcoholic fatty liver disease. PSC = primary sclerosing cholangitis. BCLC =
Barcelona Clinic Liver Cancer. N/A = not applicable.
aDefined as HCV antibody positive plus either HBV surface antigen and/or core
antibody positive.
bBCLC C and presence of extrahepatic spread were required eligibility criteria
for HCC cohort.
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follow-up. Kaplan-Meier methods were used to determine
the impact of CTCs at each cut-point and conventional
prognostic factors on overall survival. The CTC level, AFP
value of 400 ng/mL, and presence of macrovessel invasion
were used to dichotomize for univariate analyses. The
Child Pugh score and etiology of liver disease were also
examined. A p value of < 0.05 was considered statistically-
significant under log-rank tests. Sequencing coverage
depth was compared between sample types using two-
tailed t-tests assuming unequal variance. Variant calls were
reported descriptively due to small sample size.
Results
Patient characteristics
Twenty patients with a diagnosis of metastatic HCC
(HCC cohort) and 10 patients with underlying non-
malignant liver disease without cancer (NMLD cohort)
were prospectively enrolled between June 2011 and April
2012. All HCC patients were followed to date of death.
Baseline patient characteristics are shown in Table 1.
The median overall survival in the HCC cohort was
9.44 months from date of CTC blood draw. One NMLD
cohort patient with HCV cirrhosis (Hep 25) was found
to have a liver mass with adjacent portal vein thrombosis
on a surveillance ultrasound after enrollment and was
excluded based upon a suspected new diagnosis of HCC,
resulting in 9 eligible patients in the NMLD cohort. The
patient was subsequently lost to follow up. Figure 1 dis-
plays the study subject enrollment and samples tested.
CTC detection and enumeration by CellSearch
Figure 2 depicts the number of CTCs detected in each
patient. At least 1 CTC per 7.5 mL was detected in 8 of
20 (40%, 95% CI: 17%, 64%) HCC patients and 1 of 9
(11%, 95% CI: 0, 37%) eligible NMLD patients (p = 0.1,
Wilcoxon-Kruskal-Wallis rank test). At least 2 CTC per
7.5 mL were detected in 7 of 20 (35%, 95% CI: 12%,
60%) HCC patients and 0 of 9 eligible NMLD patients
(p = 0.04, Wilcoxon-Kruskal-Wallis rank test). Among
the HCC cohort patients, at least 1 CTC per 7.5 mL was
detected in 7 of 10 (70%, 95% CI: 35%, 100%) with AFP ≥
400 ng/mL, versus 1 of 10 (10%, 95% CI: 0, 33%) with
AFP < 400 ng/mL (p = 0.008). At least 1 CTC per 7.5 mL
was detected in 8 of 13 (62%, 95% CI: 31%, 92%) with
vascular invasion versus 0 of 7 without (p = 0.009)
(Wilcoxon-Kruskal-Wallis rank tests). The NMLD control
cohort patient Hep 25 who was removed for ineligibility
(due to new liver mass with thrombosis consistent with
HCC) was found to have 20 CTCs per 7.5 mL peripheral
blood. Another NMLD cohort patient with alcoholic cir-
rhosis had 1 CTC detected per 7.5 mL peripheral blood. It
is noteworthy that the single eligible NMLD control pa-
tient with detectable CTCs (1 in 7.5 mL) subsequentlydeveloped new infiltrative changes in the liver on a sur-
veillance ultrasound, raising the possibility of underlying
tumor though no formal HCC diagnosis was made before
his death of complications of cirrhosis approximately
13 months after CTC blood draw.
The median overall survival (OS) in the HCC cohort
was 9.4 months. Among HCC cohort patients with at
least 1 CTC per 7.5 mL, the median OS was 2.8 months
(95% CI: 1.08, 15.5), versus 11.3 months (95% CI: 7.49,
12.9) for those without CTCs detected, although the dif-
ference was not statistically significant (p = 0.62, Log-
Rank test) (Figure 3). In univariate analysis of CTC levels
and conventional prognostic factors (Table 2), none
showed significant effect on overall survival, though ana-
lyses were limited by small sample sizes; no further
multivariate analysis was performed.
Figure 1 Study subject enrollment and samples tested. aOne patient enrolled to NMLD control cohort was removed for ineligibility due to
new finding of liver mass with portal vein thrombosis on imaging after enrollment. CTC testing in this patient showed 20 CTCs per 7.5 mL
peripheral blood. bOne sample each of CTC and FFPE did not yield sufficient DNA for sequencing. c4 primary and 3 metastatic tumor FFPE
samples were available from 7 of the HCC cohort cases. Paired CTC WGA DNA and FFPE tumor tissue were available in 2 cases, one of which
also had PBMC available. Paired FFPE tumor tissue and PBMC were available from 2 additional cases.
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Five patients in the HCC cohort showed greater than 10
CTC per 7.5 mL detected by CellSearch. CTCs were
then isolated via IE/FACS performed on the remaining
blood samples collected from these patients. IE/FACS
was also performed on the specimen from Hep 25, the
patient removed from the NMLD cohort for the finding
of a liver mass with portal vein thrombosis. Absolute
CTC counts by CellSearch and IE/FACS for these sam-
ples are provided in Additional file 1.
CTC, PBMC, and FFPE sequencing performance
Sequencing of adequate DNA samples from CTCs, FFPE
tumor samples, and banked PBMC from the study co-
hort (Figure 1, Table 3) was performed. Paired FFPE
tumor and/or PBMC from patients with adequate CTC
DNA for sequencing were available in two cases; two
additional cases with paired FFPE tumor and PBMC
samples available without adequate CTC DNA also were
analyzed from the HCC cohort (Figure 1). SequencingFigure 2 CTC detection and enumeration by CellSearch. Figure 2 depic
cohort (A) and NMLD control cohort (B). *One patient in NMLD cohort wh
thrombosis was found to have 20 CTCs per 7.5 mL peripheral blood.performance according to sample type is displayed in
Table 3. Sequencing performance data for FFPE tumor
samples and banked PBMC (both a source of DNA not re-
quiring WGA) were combined due to small sample sizes,
for comparison to WGA DNA from CTCs (Table 3). The
mean amplicon read depth was lower (2258 versus 2954,
p < 0.01) and proportion of targeted bases with sequencing
coverage of ≥ 100x was significantly lower in CTC samples
(43%) than in FFPE tumor plus PBMC samples (87%) (p <
0.025), using two-tailed t-tests. The mean number of vari-
ant calls per sample was higher in CTC samples compared
to FFPE samples (9 vs. 2, p < 0.04), though the mean fre-
quency of individual variant alleles was significantly lower
(36% vs. 60%, p < 0.001) (two-tailed t-tests). Reproducibil-
ity of sequencing results was demonstrated by 3 samples
run in duplicate (data not shown).
Sequencing results: variants, SNPs and mutation calls
Eighty-six variants overall, 58 of which were predicted to
be protein-altering, were identified from all of the CTCts the CTC count per 7.5 mL whole blood by CellSearch in the HCC
o was removed for ineligibility due to new liver mass with portal vein
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Figure 3 Kaplan-Meier survival curve in HCC cohort by CTC strata. Overall survival was measured from date of CTC blood draw to date of
death. The median overall survival was 2.8 months in patients with CTC≥ 1/7.5 mL (95% CI: 1.08, 15.5) versus 11.3 months in patients with CTC <
1/7.5 mL (95% CI: 7.49, 12.9) though the difference was not statistically significant in this small sample (p = 0.62, Log-Rank test).
Table 2 Univariate analysis of CTC levels and conventional prognostic factors with overall survival
HCC Cohort (n = 20) Mean overall survival
(months) (standard error)
Median overall survival
(months) (95% CI)
p value (Log-Rank test)
CTC per 7.5 mL
< 1.0 (n = 12) 10.96 (1.95) 11.29 (2,69, 16.06)
1.0 (n = 8) 8.49 (3.63) 2.76 (0.72, 15.54) 0.6179
<2.0 (n = 13) 10.37 (1.89) 10.32 (3.25, 12.91) 0.8021
≥2.0 (n = 7) 9.23 (4.11) 2.20 (0.72, 15.54) 0.8510
<3.0 (n = 14) 9.74 (1.86) 9.45 (2.69, 12.91)
≥3.0 (n = 6) 10.50 (4.62) 8.26 (0.72, 29.14)
Median AFP (ng/mL)
<400 (n = 10) 11.20 (2.29) 11.32 (2.69, 16.07) 0.4058
≥400 (n = 10) 8.73 (2.92) 5.39 (0.72, 14.32)
Macrovessel invasion
No (n = 7) 10.12 (2.48) 10.32 (2.69, 12.91) 0.7493
Yes (n = 13) 10.45 (2.82) 8.58 (1.58, 15.54)
Child Pugh score (%)
A (n = 14) 10.69 (1.87) 11.32 (2.20, 15.54)
B (n = 5) 9.29 (5.39) 3.25 (0.72, 29.14) 0.7181
C (n = 1) I
Etiology of liver disease (%)
HBV (n = 5) 10.28 (3.83) 8.58 (2.20, 21.85)
HCV (n = 9) 10.41 (1.96) 12.62 (1.91, 15.54) 0.9324
HBV + HCV (n = 2) I I
ETOH (n = 1) I I
NAFLD (n = 2) I I
Unknown (n = 1) I I
Kaplan-Meier methods were used to determine the impact of CTC at each cut-point and conventional prognostic factors on overall survival. The CTC level, AFP
value of 400 ng/mL, and presence of macrovessel invasion were used to dichotomize for univariate analyses. The Child Pugh score and etiology of liver disease
were also examined. A p value of < 0.05 was considered statistically-significant under log-rank tests. No factor showed significance in univariate analysis though
analyses were limited due to small small sample sizes. Key: CI = confidence interval. ETOH = alcohol. NAFLD = non-alcoholic fatty liver disease. I = sample size
insufficient for analysis.
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Table 3 Sequencing performance by sample type
Sample type CTC WGA DNA (n = 5) FFPE Tumor DNA (n = 6) and
PBMC DNA (n = 3) (n = 9 totala)
p value (two-tailed t-test)
Mean read length 74 bp 76 bp NS
Mean mapped reads per sample 653,878 bp 668,633 bp NS
Mean amplicon read depth (std. dev) 2258 (4389) 2954 (1379) p < 0.01
Proportion with coverage > 20x 50% 97% p < 0.0002
Proportion with coverage > 100x 43% 88% p < 0.026
Mean non-synonymous variant calls per sample 9 2b p < 0.03
Mean variant allele frequency 37% 61%b p < 0.0001
aData from FFPE and PBMC DNA samples were combined for sequencing performance analyses (but not for genotype analyses) due to small sample size and
similar observed coverage. NS = not significant. bPBMC samples (germline DNA) were excluded from variant analyses, n = 3.
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were low-frequency (occurring in less than 10% of the
individual sample), among which 93% were from CTC-
derived DNA. Fifty-eight somatic, non-synonymous vari-
ants were called mutations if a matching mutation has
been described in liver cancer, if the variant shared the
same amino acid residue as a COSMIC mutation in any
cancer type, and/or if the variant allele frequency was
greater than 5% but the variant was not a known SNP
and not present in any PBMC sample [28]. Frameshift
mutations were excluded from analysis due to known
limitations of ion semiconductor sequencing to accur-
ately detect frameshift mutations. Characteristic muta-
tions in HCC (TP53, PTEN) were identified in CTC-
derived DNA from two cases. Figure 4 displays a sum-
mary of the somatic, non-synonymous mutations identi-
fied in CTC and FFPE tumor samples combined. A
listing of all somatic, non-synonymous mutations (ex-
cluding frameshift) detected according to sample type is
provided in Additional file 2. In one HCC case with
matched CTC, FFPE tumor, and PBMC DNA, 8 SNPs
were present and concordant in both FFPE tumor and
PBMC DNA; 5 of these (63%) were detected in the CTC
DNA. Neither was identified in the paired CTC DNA.
Discussion
The ability to detect and characterize malignant cells in
circulation holds enormous promise as a biomarker in
HCC, a grim cancer challenged by the inability of con-
ventional noninvasive diagnostic and staging modalities
to encompass its great clinical and biological heterogen-
eity, as well as by a scarcity of tumor tissue available for
diagnostic or research purposes. In this study, at least
one CTC was detected in 8/20 (40%) of patients with
metastatic HCC, compared to 1/9 (11%) of eligible
NMLD patients using the CellSearch System. Though
the cut-point of ≥ 1 CTC/7.5 mL did not achieve signifi-
cance between the two groups, a cut-point of ≥ 2 CTCs/
7.5 mL was significant, positive in 7/20 (35%) HCCpatients compared with none in the NMLD cohort (p =
0.04), consistent with prior reports [14,15]. The one eli-
gible NMLD control patient with CTC count of 1/
7.5 mL was subsequently found to have ultrasound find-
ings suggestive of underlying tumor, although no formal
HCC diagnosis was made, and thus he was not removed
from the control cohort. Our findings confirm the lim-
ited existing data suggesting that circulating EpCAM-
positive epithelial cells are rare in patients with non-
malignant liver diseases, and that EpCAM-positive cells
in HCC patients are generally of tumor origin [14].
Corroborating the prognostic value of EpCAM-
positive CTCs in other recent series [14,15], the detec-
tion of CTCs in the HCC cohort of this study was sig-
nificantly associated with high AFP and the presence of
vascular invasion, and there was a non-significant trend
toward poorer overall survival in patients with detectable
CTCs. These findings support the value of CTCs as a
prognostic biomarker in metastatic HCC and suggest fu-
ture potential roles for CTCs in treatment decision-
making as well as for stratification in clinical research,
which historically has been challenged by the great prog-
nostic heterogeneity of this disease [29].
The unexpected finding of high CTC levels in a patient
initially enrolled to the NMLD cohort, who subsequently
was removed for ineligibility due to the finding of a new
liver mass with vascular invasion on ultrasound suggestive
of HCC, raises the intriguing possibility that CTC detec-
tion also may be associated with vascular invasion and
poor prognosis in earlier stages of disease. This incidental
finding, along with recent results of Schulze et al. and Sun
et al. indicating prognostic value of CTC detection in pa-
tients with localized HCC [14,15], suggest an important
potential role for CTCs as a biomarker of occult vascular
invasion, recurrence risk, and overall survival in patients
with apparent localized disease undergoing evaluation for
surgery or transplantation.
Our finding that EpCAM-positive CTCs are associated
with high AFP and the presence of vascular invasion is
Figure 4 Summary of somatic, non-synonymous mutations. Occurring in CTC WGA DNA (n = 5) and/or tumor DNA (n = 6).
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cate that EpCAM-positive CTCs have biologic relevance
as a diagnostic and prognostic biomarker in HCC.
EpCAM expression and an EpCAM-positive gene ex-
pression signature are associated with poor differenti-
ation, high AFP levels, and activation of Wnt-β-catenin
signaling pathways [30-32]. EpCAM-positive HCC cells
also express markers associated with cancer stem cells
and the epithelial to mesenchymal transition, supporting
a hypothesis that EpCAM enrichment identifies stem-
like cells with potential for metastasis [15,30,31,33].
A key unanswered question is whether EpCAM is the
optimal marker for CTC enrichment in HCC. Unlike
other epithelial tumor types which demonstrate nearly
universal EpCAM expression [34], EpCAM is not
expressed on mature hepatocytes and is expressed in only
approximately 35% to 60% of HCC tumors by immunohis-
tochemistry or PCR-based methods [30,31,35-37]. Thus, it
is possible that non-EpCAM-expressing HCC cells exist in
circulation and are undetectable by technologies employ-
ing EpCAM enrichment, which may account for our in-
ability to detect CTCs in some of our HCC patients. Small
series of non-EpCAM-based CTC isolation methods, such
selection for the expression of asialoglycoprotein receptor
or pancytokeratin or by cell size, suggest numerically
higher incidence of detectable CTCs in metastatic HCC
patients than has been reported with CellSearch, though
the data are limited by small sample sizes and are not
comparative [16,17,38]. Optimal CTC isolation and en-
richment in HCC may require combining EpCAM with
other markers.Beyond using CTC detection and enumeration as a
prognostic biomarker, however, CTCs offer a dynamic
window into the evolution of metastatic disease. The ad-
vent of next-generation sequencing has revealed a remark-
able degree of heterogeneity within individual tumors and
between primary tumors and their metastases [39]. With
increasingly sensitive and precise technologies for the de-
tection and molecular profiling of rare cells, the genomic
interrogation of CTCs may offer a powerful new tool to
characterize, and someday to target, the dominant tumor
subclones responsible for treatment resistance or meta-
static progression. Heitzer et al. recently reported the first
comprehensive genomic profiling of single CTCs using
array comparative genomic hybridization and next-
generation sequencing in a study of 37 patients with meta-
static colorectal cancer [18]. Among the 6 patients with
adequate (>10) CTCs isolated for genomic profiling, con-
cordance on copy number changes and characteristic
driver mutations including PIK3CA, APC, and KRAS was
shown, along with many additional mutations in the CTCs
which were later found to be present at subclonal levels in
the primary tumors by deep sequencing. Interestingly, het-
erogeneity was observed between CTCs isolated from the
same patient at the same time-point.
This pilot study represents the first report of efficient
isolation and next-generation sequencing of CTCs in
HCC, to our knowledge. In this study, ion semicon-
ductor next-generation sequencing showed a signifi-
cantly higher proportion of targeted bases with at least
100x coverage depth among FFPE tumor and PBMC
samples (87%) compared to CTC-derived DNA samples
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ing to sample type may be due in part to the use of an
adaptor-ligation PCR WGA method which has been as-
sociated with allelic loss; alternate methods of amplifica-
tion such as multiple displacement may mitigate this
effect [40-42]. An alternate or contributory factor lead-
ing to the difference in allele frequency between sample
types, as well as to the mutational disagreements be-
tween FFPE and CTC samples, may be the inherent het-
erogeneity of individual CTCs which were pooled for
WGA from each patient [43]. WGA may also introduce
low frequency variants by artifact [40,41].
In our study, 86 variants were identified from CTC
and FFPE tumor samples. One half of the variants were
low frequency (<10%) and derived predominantly from
the CTC DNA samples. While again this finding could
be due to coverage bias or artifact arising from WGA,
these results are also consistent with the findings from
Heitzer et al. in a colorectal cancer cohort [18], which
suggest significant inter-CTC heterogeneity and could
explain the prevalence of low-frequency variants arising
from pooled DNA derived from multiple CTCs from an
individual patient. Characteristic mutations associated
with HCC (including TP53 and PTEN) were identified in
CTC-derived DNA, consistent with tumor origin [44].
The overall sequencing accuracy in this study was demon-
strated by several cases with available paired PBMC, CTC,
and tumor DNA samples showing concordance on SNP
calls, along with reproducibility of results in duplicate
runs. A significant limitation of the exploratory sequen-
cing in this pilot study, however, was its small sample size,
along with the limited proportion of cases with paired
CTC, FFPE tumor, and PBMC DNA available.
Conclusions
This study strongly supports that circulating epithelial
cells are detectable in HCC patients, including via the
CellSearch assay; and that these cells are EpCAM-
positive tumor cells in circulation, rather than benign
epithelial cells released in the setting of liver injury.
These findings are based on significant CTC detection
in HCC but not in NMLD cohorts, associations between
CTC detection and HCC prognostic markers, and the
demonstration of characteristic HCC mutations in DNA
derived from purified CTCs. The significant association
with macrovessel invasion and elevated AFP in this
study, along with a trend towards poorer survival, indi-
cate the potential value of CTC detection as a prognostic
biomarker in metastatic HCC. Prospective analyses of
CTCs in earlier stages of disease are warranted to deter-
mine surrogacy for vascular invasion in patients undergo-
ing evaluation for surgery or liver transplantation. In
parallel, we demonstrate that CTCs offer a source of non-
invasive tumor DNA for next-generation sequencing andmolecular profiling efforts in HCC. Future studies to de-
termine the optimal CTC isolation technology, cut-points
by assay and population, and methods for single-cell CTC
molecular characterization are essential to develop CTCs
as a clinical biomarker as well as a research tool in this
grim, complex disease in urgent need of new biomarkers
and therapeutic targets.
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